1
|
Madariaga MLL, Guthmiller JJ, Schrantz S, Jansen MO, Christensen C, Kumar M, Prochaska M, Wool G, Durkin-Celauro A, Oh WH, Trockman L, Vigneswaran J, Keskey R, Shaw DG, Dugan H, Zheng NY, Cobb M, Utset H, Wang J, Stovicek O, Bethel C, Matushek S, Giurcanu M, Beavis KG, di Sabato D, Meltzer D, Ferguson MK, Kress JP, Shanmugarajah K, Matthews JB, Fung JF, Wilson PC, Alverdy JC, Donington JS. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med 2021; 289:559-573. [PMID: 33034095 PMCID: PMC7675325 DOI: 10.1111/joim.13185] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 08/11/2020] [Accepted: 09/08/2020] [Indexed: 12/28/2022]
Abstract
BACKGROUND Convalescent plasma therapy for COVID-19 relies on transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. METHODS Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed-effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19. RESULTS Donor antibody titres ranged from 0 to 1 : 3892 (anti-receptor binding domain (RBD)) and 0 to 1 : 3289 (anti-spike). Higher anti-RBD and anti-spike titres were associated with increased age, hospitalization for COVID-19, fever and absence of myalgia (all P < 0.05). Fatigue was significantly associated with anti-RBD (P = 0.03). In pairwise comparison amongst ABO blood types, AB donors had higher anti-RBD and anti-spike than O donors (P < 0.05). No toxicity was associated with plasma transfusion. Non-ECMO recipient anti-RBD antibody titre increased on average 31% per day during the first three days post-transfusion (P = 0.01) and anti-spike antibody titre by 40.3% (P = 0.02). CONCLUSION Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titre to COVID-19. Despite variability in donor titre, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion amongst COVID-19-infected patients is needed.
Collapse
Affiliation(s)
- M L L Madariaga
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - J J Guthmiller
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - S Schrantz
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - M O Jansen
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - C Christensen
- Department of, Pathology, University of Chicago, Chicago, IL, USA
| | - M Kumar
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - M Prochaska
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - G Wool
- Department of, Pathology, University of Chicago, Chicago, IL, USA
| | - A Durkin-Celauro
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - W H Oh
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - L Trockman
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - J Vigneswaran
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - R Keskey
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - D G Shaw
- Committee on Immunology, University of Chicago, Chicago, IL, USA
| | - H Dugan
- Committee on Immunology, University of Chicago, Chicago, IL, USA
| | - N-Y Zheng
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - M Cobb
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - H Utset
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - J Wang
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - O Stovicek
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - C Bethel
- Clinical Microbiology and Immunology Laboratory, University of Chicago, Chicago, IL, USA
| | - S Matushek
- Clinical Microbiology and Immunology Laboratory, University of Chicago, Chicago, IL, USA
| | - M Giurcanu
- Department of Public Health Sciences, University of Chicago, Chicago, IL, USA
| | - K G Beavis
- Biological Sciences Division, Department of Pathology, University of Chicago, Chicago, IL, USA
| | - D di Sabato
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - D Meltzer
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - M K Ferguson
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - J P Kress
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - K Shanmugarajah
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - J B Matthews
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - J F Fung
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - P C Wilson
- Department of, Medicine, University of Chicago, Chicago, IL, USA
| | - J C Alverdy
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| | - J S Donington
- From the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA
| |
Collapse
|
2
|
Blasberg JD, Pass HI, Flores RM, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11019 Background: Plasma osteopontin (OPN) levels in advanced NSCLC correlate with response to therapy and survival but the role plasma OPN in diagnosis or monitoring of early stage NSCLC has not been investigated. We hypothesize that plasma OPN levels are elevated in early stage NSCLC and that resection results in a measurable reduction. Methods: Pre-operative (pre-op) plasma OPN levels (ng/ml) were measured by ELISA (IBL-Japan) in a discovery set of 60 early stage NSCLC patients and compared to 56 current or former smokers. Pre-op OPN was validated in an independent cohort of 78 resectable NSCLC patients. The pre-op OPN level in the latter cohort was compared to matched postoperative (post-op) OPN levels to monitor the impact of surgery on the biomarker. Results: Discovery set pre-op OPN (271+31) was significantly higher than in smokers (40+2)(p=.001). Pre-op OPN was similar in the validation cohort (357+31, p=.055, demographics in Table ). Post-op OPN (189+19) measured at mean of 23 weeks (range 2–105) was significantly lower than pre-op (p<.0001). Time from surgery significantly impacted post-op OPN, with OPN<6 weeks post-op (282+30) higher than OPN>6 weeks post-op (155+18)(p<.0001). After 6 weeks post-op, resected stage I patients (N=45) had a significant decrease in OPN levels from 373+45 to 142+21 (p<.0001). Multivariate analysis ( Table ) noted a significant correlation between age, albumin and pre-op OPN, and between albumin and pre-op OPN and >6 weeks post-op OPN. No correlation was noted between gender, smoking, histology, diabetes or stage and the pre- or >6 weeks post-op OPN. Conclusions: Plasma OPN levels in early stage NSCLC patients are significantly elevated compared to smokers. The elevated pre-op OPN levels were validated in an independent cohort of early stage NSCLC patients. A significant decrease in OPN was noted following resection. Peri-operative reductions in plasma OPN may serve as a marker for response to therapy and warrant investigation into prognostic significance in early stage NSCLC. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- J. D. Blasberg
- NYU, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - H. I. Pass
- NYU, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - R. M. Flores
- NYU, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. S. Donington
- NYU, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
3
|
Flores RM, Riedel E, Donington JS, Krug L, Rosenzweig K, Adusumilli P, Carbone M, Rusch VW, Pass HI. Frequency of use and outcome of surgical resection in the management of malignant mesothelioma in a community-based population: Results in 5,937 patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7510] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7510 Background: Multimodality therapy of mesothelioma patients treated at specialized tertiary hospitals report surgical resection rates of 42% (Flores RM et al. Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center. J Thorac Oncol 2007;2(10):957–965.). Treatment strategies in the community are less well defined and surgical expertise is not readily available. We undertook this study to evaluate the rate of surgical resection and its association with survival in a non-tertiary based population. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was searched from 1990 - 2004. Variables analyzed included age, sex, race, year of diagnosis, laterality, vital status, stage, surgery, and reasons for no surgery. The association of resection on overall survival was estimated by the Kaplan-Meier method and examined in a Cox proportional hazards model adjusting for covariates. Results: Pathologically proven malignant pleural mesothelioma was identified in 5,937 patients: 1,166 women, 4,771 men; median age was 70 years. Surgical resection rate was 11% (n=636). Univariate analysis demonstrated a median survival of 13 months with surgical resection and a median survival of 7 months in the non-resected group (p<0.0001). Multivariate analysis demonstrated improved survival for surgically resected patients (HR 0.7, p<0.0001), controlling for age, gender, and stage. Conclusions: Surgical resection was associated with improved survival when controlling for age, stage, and gender. However, the rate of surgical resection was much lower in the community when compared to tertiary referral centers. Treatment efforts should be focused on a multidisciplinary approach which includes surgical evaluation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. M. Flores
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - E. Riedel
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - J. S. Donington
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - L. Krug
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - K. Rosenzweig
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - P. Adusumilli
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - M. Carbone
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - V. W. Rusch
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| | - H. I. Pass
- Memorial Sloan-Kettering Cancer Center, New York, NY; New York University, New York, NY; University of Hawaii, Honolulu, HI
| |
Collapse
|